Key Highlights

  • Avalyn Pharma Inc. (Nasdaq: AVLN) is seeking to raise approximately USD 181.8 million through an IPO priced at USD 17.00 per share, with net proceeds directed toward advancing its three clinical-stage inhaled antifibrotic programs targeting pulmonary fibrosis
  • The company's lead candidate, AP01 (inhaled pirfenidone), has demonstrated near-stabilization of lung function in patients with IPF at 48 weeks in the ATLAS Phase 1b trial, with long-term OLE data exceeding four and a half years showing a durable and consistent tolerability profile
  • Avalyn's differentiated inhaled delivery approach is designed to achieve superior lung exposure at substantially lower doses than oral counterparts, with AP02 demonstrating 27-fold higher lung concentrations than oral nintedanib at a fraction of the approved dose
  • The company carried a net loss of USD 85.2 million for fiscal year 2025, with an accumulated Deficit of USD 265.4 million, and has never generated Revenue; post-IPO, management projects the combined Capital base will fund operations into 2029
  • Pulmonary fibrosis currently affects approximately 300,000 people in the United States, with the oral antifibrotic market generating over USD 4.0 billion in global sales in 2024, representing a significant commercial opportunity for a tolerability-differentiated inhaled alternative

 

A Rare Respiratory Disease Company Reaches the Public Stage

Pulmonary fibrosis is one of medicine's more unforgiving diagnoses. With a median survival of three to five years following diagnosis, shorter than many forms of cancer, it carries enormous medical and human weight. The three currently approved oral antifibrotic therapies slow but do not halt disease progression, and their tolerability challenges are well documented. Around 50% of patients who initiate treatment with available oral agents discontinue within one year due to gastrointestinal and other systemic side effects. Only approximately 30% of patients with IPF are actively treated at any given time.

Avalyn Pharma, a clinical-stage biopharmaceutical company founded in 2011 and headquartered in Boston, Massachusetts, has spent over a decade developing an answer to this problem. Its thesis is straightforward: if the same active molecules in approved oral antifibrotics can be delivered directly to the lungs via inhalation, at substantially lower systemic doses, the disease can be targeted more precisely while the side effects that drive discontinuation are reduced. The company's IPO on the Nasdaq Global Market under the ticker AVLN represents the first time this inhaled antifibrotic thesis will be tested in the public markets.

 

Industry and Macro Context: A Large Market with a Tolerability Problem

The global pulmonary fibrosis treatment landscape is dominated by two molecules: pirfenidone, marketed as ESBRIET by Legacy Pharma and Genentech, and nintedanib, marketed as OFEV by Boehringer Ingelheim. A third agent, nerandomilast, marketed as JASCAYD, received FDA approval in 2025. ESBRIET and OFEV generated more than USD 4.0 billion in combined gross global sales in 2024, making pulmonary fibrosis one of the more commercially validated rare respiratory disease markets in the world.

The clinical problem, however, is persistent. Oral pirfenidone is associated with nausea, photosensitivity, rashes, and liver enzyme elevations that frequently require dose reductions or permanent discontinuations. Oral nintedanib carries diarrhea rates of 61% to 76% across registrational studies and has its own hepatic and cardiovascular warnings. Nerandomilast faces similar GI tolerability challenges, with diarrhea occurring in approximately 40% of patients and rising to 50% to 60% when combined with nintedanib. The pattern across all three approved agents is consistent: they slow progression but cannot be used durably by a large proportion of patients due to systemic toxicity.

This tolerability gap is the market Avalyn is targeting. Its approach draws a direct parallel to the transformation of asthma and COPD therapy over the past six decades, where successive generations of inhaled formulations displaced oral agents because they delivered superior efficacy at the site of disease with dramatically reduced systemic exposure. Avalyn is betting that a similar generational shift is both clinically possible and commercially compelling in pulmonary fibrosis.

 

Core Analysis: Three Programs, One Platform, One Compelling Hypothesis

Avalyn's pipeline consists of three wholly owned inhaled candidates, all leveraging an exclusive license to PARI Pharma's eRapid Nebulizer System with eFlow Technology for delivery. The PARI exclusivity is strategically significant: the proprietary device would be included in any FDA-approved product label, creating a high-barrier drug-device combination that generic competitors would need to replicate entirely, not just the drug formulation.

AP01 (inhaled pirfenidone) is the most clinically advanced candidate and is currently being evaluated in MIST, a global Phase 2b clinical trial in patients with progressive pulmonary fibrosis. The ATLAS Phase 1b trial and its ongoing open-label extension have established a compelling preliminary profile. At the AP01 100 mg BID dose, patients demonstrated a change in FVC of only negative 0.4% or 34 mL at 48 weeks, compared to the 200 mL per year decline typically observed in untreated patients with pulmonary fibrosis and the 118 mL to 265 mL decline observed with oral pirfenidone across registrational trials. HRCT imaging data from ATLAS showed stabilization or Reversal of lung fibrosis scores in over 70% of patients treated with AP01, suggesting a potential disease-modifying effect not seen with current oral agents. The OLE trial, now running for more than four and a half years, shows 23 of the original 100 enrolled patients continuing on AP01 100 mg BID, with many exceeding six years post-diagnosis against a median survival of three to five years.

AP02 (inhaled nintedanib) has completed two Phase 1 Clinical Trials demonstrating favorable tolerability, with no diarrhea, bronchospasm, or meaningful oxygen desaturation events observed through the highest dose studied of 8 mg BID. Pharmacokinetic data show AP02 achieves 27-fold higher lung Cmax and AUC than oral nintedanib at a fraction of the approved dose, while delivering 17-fold to 26-fold lower systemic exposure. The AURA Phase 2 trial in IPF patients dosed its first patient in the first quarter of 2026, with data expected in late 2027.

AP03 is a fixed-dose combination of inhaled pirfenidone and inhaled nintedanib, drawing on validated preclinical evidence that the two agents exhibit additive or synergistic antifibrotic activity when combined. The primary obstacle for oral combination has been overlapping GI toxicity, which led to approximately one-third of patients discontinuing in the INJOURNEY Phase 4 combination trial after only 12 weeks. By delivering both agents directly to the lungs at lower systemic doses, Avalyn believes AP03 could overcome this tolerability barrier while delivering enhanced efficacy. A Phase 1 trial is planned for late 2026, with data expected in the second half of 2027.

 

Financial and Market Implications: Pre-Revenue, But Well-Capitalized

Avalyn enters the public markets as a pre-Revenue clinical-stage company with a widening Investment in its pipeline. Total operating expenses increased from USD 57.1 million in 2024 to USD 91.3 million in 2025, driven primarily by the acceleration of the AP01 Phase 2b MIST trial and the initiation of AP02 AURA. R&D expenses rose from USD 45.8 million to USD 76.6 million, with AP01 accounting for USD 50.2 million of direct program costs in 2025 alone. Net loss widened to USD 85.2 million from USD 49.7 million the prior year, and the accumulated Deficit reached USD 265.4 million as of December 31, 2025.

The post-IPO Capital structure is meaningfully stronger. At year-end 2025, the company held USD 138.4 million in cash, cash equivalents, and marketable securities. The USD 15.0 million initial Tranche drawn under a USD 30.0 million term Loan with Banc of California in February 2026, combined with the approximately USD 181.8 million in estimated net IPO proceeds at the USD 17.00 midpoint price, brings the pro forma as-adjusted cash position to approximately USD 335.1 million. Management has guided that this combined Capital base funds operations into 2029, providing runway through AP01 Phase 2b topline data in the second half of 2027, AP02 Phase 2 data in late 2027, and AP03 Phase 1 data in the second half of 2027. The explicit Capital allocation includes approximately USD 150.0 million toward AP01 through Phase 2b topline data and into Phase 3, approximately USD 90.0 million for AP02 through Phase 2 topline data and into Phase 3, and approximately USD 10.0 million for AP03 through Phase 1.

For investors, the valuation framework at USD 17.00 per share implies a post-IPO Market Capitalisation of approximately USD 628.1 million on 36.9 million shares outstanding. This represents a pre-Revenue biotech valuation that is highly dependent on the positive read-through from MIST data in the second half of 2027. At that juncture, if AP01 achieves statistically significant FVC stabilisation versus placebo, the stock could command a meaningful rerating as the company transitions from a clinical-stage asset to a near-commercial programme with established Phase 3 design.

 

Strategic Outlook: The Generational Shift Thesis

Avalyn's long-term strategic vision extends well beyond AP01 and AP02. The company frames its product development philosophy around the successive generational advancement seen in COPD and asthma treatment, where systemic oral agents gave way to single inhaled therapies, then dual combinations, and ultimately triple fixed-dose combinations that now define the standard of care. AP01 and AP02 represent Generation Two for pulmonary fibrosis. AP03 represents Generation Three. The company has also identified rheumatoid arthritis-associated ILD and chronic lung allograft dysfunction as potential future indications where the same lung-targeted delivery approach could address high unmet need.

The intellectual property position supporting this strategy is defensible across multiple dimensions. The company holds over ten issued U.S. patents covering pirfenidone formulations extending beyond 2032, additional nintedanib formulation patents extending to 2034 and 2039, and pending applications extending protection potentially to 2043 and beyond. The PARI device exclusivity adds a layer of protection that is structurally difficult to replicate, given that generic inhaled products are among the most technically and regulatorily complex to approve in the United States. To date, only a very small number of generic inhaled products have received FDA approval and reached commercial markets.

 

A Differentiated Science Story with Binary Clinical Milestones

Avalyn Pharma's IPO is the market's first opportunity to own a pure-play inhaled antifibrotic platform with genuine long-term clinical evidence, a differentiated delivery mechanism, and a Capital structure strong enough to reach multiple data readouts. The Investment case rests on a scientifically grounded hypothesis, four and a half years of open-label tolerability data that represent the longest continuously durable clinical dataset in pulmonary fibrosis, and a robust Comparative Advantage in drug-device combination exclusivity.

The fundamental risk is also clear. MIST is a pivotal study for the programme. If Phase 2b data Fail to demonstrate statistically significant FVC benefit versus placebo, the risk-reward calculus changes materially. Until that verdict arrives in the second half of 2027, AVLN will trade as a binary event story with a well-resourced Balance Sheet and a credible scientific narrative. For investors with conviction in the inhaled antifibrotic thesis, the IPO provides a rare early-stage entry point into a programme that has already demonstrated more than four years of durability data, unlike most Phase 2 Assets at the time of listing.